Efficacy On Chronic Obstructive Pulmonary Disease Patients At Stable Stage Treated With Yi Fei Moxibustion

Objective By investigate the frequency of acute exacerbations of patients with stable COPD, lung function, dyspnea score, clinical symptoms, 6-minute walk distance,CAT,immune function multidimensional indicators, to evaluate the efficacy of Yi Fei Moxibustion in patients with COPD at stable stage.Methods Using randomized controlled trial design, the stable COPD patients were divided into treatment group and the control group,30 cases in each group,30 cases in the control group were taken regular treatment for 3 months.The treatment group were treated by Yi Fei Moxibustion besides conventional treatment for 3 months.We observed Yi Fei Moxibustion clinical efficacy for the treatment of patients with stable COPD form acute exacerbation frequency,lung function,dyspnea score,clinical symptoms,6-minute walk distance,CAT,immune function(CD3、CD4/CD8、Ig G and Ig M). Using SPSS18.0 statistical analysis.Results A total of 60 patients, four cases of loss, which were in line with the program’s total 56 cases,with the treatment group of 29 cases and 27 cases in the control group.No significant difference in the two groups at baseline,which were comparable. Clinical efficacy as follows:1. acute exacerbation Before treatment,there was no significant difference between comparable(P>0.05). After treatment, the number of exacerbations comparisons between the two groups were significantly different(P<0.05). After treatment,the treatment group acute exacerbation number of nearly three period 1 year after the conversion of less than last year is statistically significant(P<0.05),and the number of years acute exacerbation reduction before the treatment of showed no statistically difference in the control group(P> 0.05).2. Pulmonary Function Before treatment,the two groups of FVC, FEV1, FEV1% of the indicators were not statistically different(P>0.05).After treatment,two groups of FVC, FEV1, FEV1% of the indicators showed no significant difference(P>0.05).After treatment,the two groups of FVC FEV1 and FEV1% compared with before showed no significant difference(P>0.05).3. MMRC Before treatment, the two groups had no statistical difference in dyspnea score(P>0.05).After treatment, dyspnea score reduction between the two groups were significantly different(P<0.05).After treatment, the treatment group dyspnea scores improve significantly than before treatment(P<0.05),and the control group showed no significant difference before and after treatment(P>0.05).4. Clinical symptoms and signs with total score Statistical analysis of the two groups total score of clinical symptoms was no difference before treatment(P>0.05).After repeated measures analysis of variance between the treatment of the symptoms of the two groups at different time points(treatment for one month, treatment for tro months, treatment for three months) total score was statistically significant decrease(P<0.05),with significant time effect(P<0.01).There was significant differences in individual symptoms,such as cough,expectoration,wheezing,chest tightness and fatigue(P<0.05),while no significant differences in cyanosis and shortness of breath score(P>0.05).5. 6-minute walk distance Before treatment,the two groups of 6-minute walk distance was no significant difference(P>0.05).After treatment,there was statistical difference between the two groups 6 minutes walking distance(P<0.05).After treatment, the treatment group 6 minutes walking distance improved Significantly than before treatment(P<0.01),and the control group 6 minutes walking distance than before treatment improved significantly(P<0.05).6. CAT questionnaire Before treatment,the two groups had no statistical difference integral CAT questionnaire(P>0.05). After treatment, CAT questionnaire scores decreased between the two groups were no significantly difference(P<0.05). After treatment, the treatment group compared with the previous CAT integral improve significantly(P<0.01),CAT scores than the control group before treatment improved significantly(P<0.05).7. T cell subsets and immunoglobulin Before treatment, two groups T cell subsets CD3, CD4 / CD8 was no significant difference(P>0.05).After treatment,the two groups of T cell subsets CD3, CD4 / CD8 were significant differences(P<0.05).After treatment, the treatment group CD3, CD4 / CD8 increased significantly compared with before treatment(P <0.01),and the control group T cell subsets CD3, CD4 / CD8 showed no significant difference before treatment(P>0.05).Before treatment,the two groups Ig G, Ig M showed no significant difference(P>0.05).After treatment,the two groups Ig M showed significant differences(P<0.05), whereas Ig G showed no significant difference between groups(P>0.05).After treatment,the treatment group Ig G, Ig M increased significantly than before treatment(P<0.01), and Ig G, Ig M showed no significant difference in control group compared with pre-treatment(P> 0.05).Conclusion 1. Treatment by Yi Fei Moxibustion with stable COPD had reduced the number of exacerbations,improved cough,sputum,wheezing,fatigue and other symptoms,and improved dyspnea, reduced CAT scores and improve quality of life.2. Yifei moxibustion had increased stable COPD six minutes walking distance and increased exercise tolerance in patients.3. Yifei moxibustion treatment of COPD has a certain effect, its mechanism may be related to improve immune function in patients.